Navigation Links
Omeros Appoints New Vice President of Clinical Development
Date:8/5/2009

SEATTLE, Aug. 5 /PRNewswire/ -- Omeros Corporation today announced the appointment of Stephen R. Murray, M.D., Ph.D. as Vice President of Clinical Development. Dr. Murray will oversee clinical trial strategies and protocols at Omeros, and currently is leading the ongoing clinical studies for Omeros' PharmacoSurgery(TM) product candidates. These include OMS103HP, the Company's lead candidate being evaluated in a Phase 3 clinical program for improved joint function and pain reduction following arthroscopic surgery, OMS302 in a Phase 2 program for use in cataract surgery, and OMS201 in a Phase 1/2 program for use in uroendoscopy.

"Dr. Murray brings a wealth of experience in the pharmaceutical industry, having successfully directed a number of development programs in both large and small pharmaceutical companies," said Gregory A. Demopulos, M.D., Chairman & CEO of Omeros. "Dr. Murray will work closely with our team members to continue building the long-term value of Omeros and our products."

"Omeros is poised to deliver important new treatments to patients through its PharmacoSurgery platform," said Dr. Murray. "In addition, we have several preclinical central nervous system and inflammation programs that have the potential to address significant unmet medical needs. This is an important time for Omeros and I'm excited to play a role here."

Prior to Omeros, Dr. Murray served in various positions, most recently as Chief Medical Officer at Memory Pharmaceuticals, a biopharmaceutical company that developed treatments for central nervous system disorders and was acquired by Hoffman-La Roche Inc. in January 2009. Before that, Dr. Murray held various positions at Pfizer Global Pharmaceuticals, including senior medical director and therapeutic team leader for schizophrenia. Dr. Murray received his M.D. and Ph.D. in molecular and cellular biology from the Medical University of South Carol
'/>"/>

SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
2. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
3. Omeros and BlueCrest Announce $20 Million Debt Facility
4. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
5. Omeros Appoints David A. Mann to its Board of Directors
6. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
7. Oncothyreon appoints Diana Hausman as Vice President of Clinical Development
8. Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
9. Brookstone Pharmaceuticals Appoints New Corporate Position
10. PDI Appoints Gerald P. Belle as Lead Independent Director
11. Laureate Pharma Appoints Daniel E. Leone as Vice President of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Fried, Frank, Harris, Shriver & Jacobson LLP ... joined the Firm as a partner in the Intellectual ... York office. Mr. Lewis concentrates on patent ... other intellectual property and general litigation. A trained chemical ... plaintiffs and defendants in a range of technology-related sectors ...
(Date:3/3/2015)... MA (PRWEB) March 03, 2015 HubCast® ... Supply Chain, today announced the expansion of its Global ... color-matched print to 850 the world’s largest cities across ... Chain extends to 137 countries providing global enterprises ease, ... print procurement process from online order to real-world delivery ...
(Date:3/3/2015)... N.J. , March 3, 2015  Thingee Corporation, ... will be delivering a presentation entitled, "Technology Adoption: Making ... Thriving through Innovations and Technology ,  in ... March 11 to 13, 2015. Audiences looking to learn ... effectively will want to be in the audience for ...
(Date:3/3/2015)... AtheroNova Inc. (OTCQB: AHRO) today announced that the ... under Chapter 11 of the U.S. Bankruptcy Code in the ... , Santa Ana division (the "Bankruptcy ... are expected to be jointly administered. The Company ... sale process, for all or substantially all of its assets ...
Breaking Biology Technology:Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 2HubCast Expands Global Print Supply Chain: Launches New Product Suite 3HubCast Expands Global Print Supply Chain: Launches New Product Suite 4Thingee to present at 11th Annual Synergistix Users Conference 2AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 2AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 3AtheroNova and its Subsidiary File for Chapter 11 Bankruptcy Protection 4
... Mass casualty incidents --,such as terrorist attacks, ... hurricanes -- raise the life-and-death reality that,existing medical ... all who,need it. One of the most critical ... respiratory support., Disaster specialists and health care ...
... CJPS Enterprises, LLC, (http://www.CJPS-Enterprises.com ), the ... (http://www.MichiganPipeline.com ) is announcing a new service ... their business, or looking to,invest in Michigan ... the existing resources available on the Michigan ...
... PT. RICHMOND, Calif., Oct. 8 Transcept Pharmaceuticals,Inc., ... P. Soloway, Senior Vice President and Chief Financial ... Second Annual Hidden,Gems Conference in New York City ... Time., An audio webcast of the presentation ...
Cached Biology Technology:Allied Healthcare Launches First of Line of Ventilators Designed to Meet Demands of Mass Casualty Incidents 2Allied Healthcare Launches First of Line of Ventilators Designed to Meet Demands of Mass Casualty Incidents 3The Michigan Life Sciences Pipeline Announces 'The Funding Place(TM)' and Other Resources to Connect Investors and Startups 2Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference 2
(Date:3/4/2015)... 04, 2015 Research and Markets ... the "Global Biometrics Market Forecast and Opportunities, ... The market for biometric authentication systems is projected ... till 2020 The driving forces for ... needs, government projects and constant development in technology. ...
(Date:3/3/2015)... FOREST, Calif. , March 3, 2015 ... the leading provider of advanced cryogenic logistics ... markets including immunotherapies, stem cells, cell lines, ... and reproductive medicine, today announced the expansion ... Cancer Research Centers, ("Fred Hutch") Clinical ...
(Date:3/2/2015)... JOSE, Calif. , March 2, 2015 /PRNewswire/ ... the leading developer of human interface solutions, today ... technology that is designed to enable rapid and ... Natural ID™ module for gaming is a turnkey ... ODMs the ability to quickly integrate fingerprint ID ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3
... they,ve been sneaking The highly social cichlid ... where non-parents contribute to rearing the offspring of the ... male subordinates never gained paternity in the field. A ... PLoS ONE , reveals that some offspring from ...
... from the University of Utah has received a two-year, $275,000 ... novel research that may help to uncover a viral cause ... These studies will use an advanced technology called deep sequencing ... progressive multiple sclerosis. Multiple sclerosis (MS), which affects an ...
... , The U.S. Food and Drug Administration (FDA) ... Healthcare of Atlanta, Emory University and Saint Joseph,s ... grant to foster the development of medical devices ... award will launch the new Atlanta Pediatric Device ...
Cached Biology News:NIH grant will allow researchers to look for viral cause of most severe form of multiple sclerosis 2FDA grant launches Atlanta Pediatric Device Consortium 2FDA grant launches Atlanta Pediatric Device Consortium 3FDA grant launches Atlanta Pediatric Device Consortium 4
Applications: Beadlyte® assay Stability: 2 years at 4°C (lyophilized) or 6 months at -20°C (rehydrated) ...
Human acetylcholine receptor (AChR)-alpha. Exhibits homogenous, high affinity,binding to the receptor. Binds weakly to a64-78. Inhibits binding of many,myasthenia gravis sera to human AChR....
Dnase and Rnase free...
...
Biology Products: